ActiveMSers Forums  

Go Back   ActiveMSers Forums > ActiveMSers.org Forums > General

Reply
 
Thread Tools Display Modes
  #1  
Old 02-25-2020, 04:19 PM
ActiveMSers's Avatar
ActiveMSers ActiveMSers is online now
Dave @ ActiveMSers
 
Join Date: Jun 2008
Location: Albuquerque, NM
Posts: 3,987
Default DMTs for primary progressive MS (Norwegian Perspective)

Disease-modifying treatments for primary progressive multiple sclerosis (PPMS). A health technology assessment

Publisher
National Institute of Public Health,
2019. On commission from
Bestillerforum RHF.

Authors
Ohm IK, Tjelle TE, Rose C, Hamidi V
Hagen G, , Fretheim, A
Clinical experts
B L, Celius EG, Holmy T, Midgard R

Objective
The objective for this health technology assessment was to evaluate clinical efficacy and cost effectiveness for disease-modifying drugs for the treatment of primary progressive multiple sclerosis (PPMS).

Key findings and conclusions
We have systematically collected and reviewed the evidence for clinical efficacy for disease modifying treatments for PPMS.

We included three randomised placebo-controlled trials that each compare the effect of one medication (either fingolimod, ocrelizumab or rituximab, respectively) with placebo.

For each of the three drugs, we calculated the risk ratios for confirmed disease progression. We also report results in the form of hazard ratios. Our results show that ocrelizumab and rituximab may reduce the risk of confirmed disease progression more than placebo. In total, the results do not give us good reason to assume that one drug is better than the other.

Fingolimod may also reduce the risk of confirmed disease progression, although to a lesser degree than for ocrelizumab and rituximab. We find these results to be less convincing than for ocrelizumab and rituximab.

We have not conducted a full health economic evaluation as we do not have strong reasons to believe that one specific drug is better or worse than the other, and because rituximab is substantially less costly than the two other treatments.

FULL ARTICLE (FREE PDF):
https://www.fhi.no/contentassets/06c...-sclerosis.pdf
__________________
Dave Bexfield
ActiveMSers
Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Forum Jump


All times are GMT -4. The time now is 05:57 AM.


Powered by vBulletin® Version 3.7.0
Copyright ©2000 - 2020, Jelsoft Enterprises Ltd.
ActiveMSers